Medepidol

Hydromorphone, the active ingredient in Medepidol, is an opioid analgesic presented as an oral dosage form for oral use. It provides analgesia for patients with moderate to severe pain.

GNH USA supplies Medepidol as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydromorphone is an opioid analgesic used to manage pain of varying origins. - Acute postoperative pain: delivers rapid relief of severe pain following surgery. - Cancer‑related pain: helps control moderate to severe pain associated with malignancies. - Severe chronic non‑cancer pain: provides long‑term analgesia when other treatments are insufficient.

Hydromorphone may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: feeling of sickness or urge to vomit. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or fatigue. - Dry mouth: reduced salivation leading to a parched feeling.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing dizziness. - Dependence or addiction: potential for misuse with prolonged use. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing or dispensing Hydromorphone, consider the following safety measures. - Assess pain severity: confirm that pain is moderate to severe before initiating therapy. - Monitor respiratory function: watch for signs of slowed breathing, especially in opioid‑naïve patients. - Evaluate renal and hepatic function: adjust use if organ impairment is present. - Avoid concurrent CNS depressants: limit use with benzodiazepines or alcohol. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Hydromorphone can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other opioids: combined use can cause profound respiratory depression. - Benzodiazepines or barbiturates: increase risk of central nervous system depression. - Monoamine oxidase inhibitors (MAOIs): may precipitate severe hypotension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise hydromorphone plasma levels. - CNS stimulants (e.g., certain antidepressants): can mask sedation, requiring dose adjustments. - Anticholinergic agents: may exacerbate constipation, necessitating prophylactic laxatives.